Molecular Imaging Directed, 3D Ultrasound-guided, Biopsy System

分子成像引导、3D 超声引导、活检系统

• 批准号: 8984870
• 负责人: BAOWEI FEI
• 金额: $ 3.25万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8984870
• 关键词: Address; Affect; Age; Animal Experiments; Animals; Appearance; Benign; Biopsy; Brachytherapy; Cancer Detection; Carcinoma; Clinical Trials; Cold Therapy; Collaborations; Computer software; Core Biopsy; Databases; Devices; Diagnosis; Dimensions; Disease; Disease Management; Face; Human; Image; Image Guided Biopsy; Imaging Techniques; Imaging technology; Joints; Kidney; Liver; Location; Lung; Malignant Neoplasms; Malignant neoplasm of prostate; Maps; Measures; Mechanics; Medical; Methods; Modeling; Molecular; Needles; Ontario; Organ; PUVA Photochemotherapy; Patients; Phase II Clinical Trials; Physicians; Poaceae; Positioning Attribute; Positron-Emission Tomography; Procedures; Prostate; Recruitment Activity; Research; Research Institute; Risk; Sampling Errors; Shapes; Speed; System; Techniques; Technology; Testing; Thermal Ablation Therapy; Three-Dimensional Image; Time; Tissues; Tracer; Transrectal Ultrasound; Ultrasonography; United States National Institutes of Health; Universities; base; blind; cancer therapy; cost; image guided; image registration; improved; innovation; local maxima; man; men; minimally invasive; molecular imaging; multimodality; novel; programs; prostate biopsy; radiofrequency; spectroscopic imaging; three-dimensional modeling; tumor; two-dimensional; vector; young man

DESCRIPTION (provided by applicant): Prostate cancer affects 1 in 6 men in the USA. Every man over the age of 45 is at risk for prostate cancer. Systematic transrectal ultrasound (TRUS)-guided biopsy is the standard method for a definitive diagnosis of prostate cancer. More than 1.2 million prostate biopsies are performed annually and the medical cost is more than two billion dollars each year. However, this technique has a significant sampling error and is characterized by low sensitivity (39-52%). This "blind" biopsy approach can miss 30% of prostate cancers. As a negative biopsy does not preclude the possibility of a missed cancer, both the physicians and patients face challenges in making treatment decisions. Due to the increasing number of younger men with potentially early and curable prostate cancer, this problem must be addressed in order to improve cancer detection rate. At our NIH/NCI-supported Emory Molecular and Translational Imaging Center, positron emission tomography (PET) with a new molecular imaging tracer FACBC has shown very promising results for prostate cancer detection in human patients. We hypothesize that FACBC PET molecular images can be incorporated into ultrasound-guided biopsy for improved cancer detection. The proposed research is to develop a molecular image-directed, 3D ultrasound-guided system for targeted biopsy of the prostate. Specific Aim 1: To modify a real-time, mechanically assisted, 3D ultrasound-guided device. Compared to conventional 2D image guidance, 3D images of the prostate will be used to guide the biopsy. Specific Aim 2: To develop fast deformable and statistical appearance model based segmentation methods for 3D ultrasound images of the prostate. Statistical shape models will be developed from our database and will be used to guide automatic segmentation of the prostate. Specific Aim 3: To combine FACBC molecular images with 3D ultrasound for targeted biopsy. New deformable image registration methods based joint saliency map and fuzzy point correspondence will be developed in order to solve major limitations of mutual information based image registration. Specific Aim 4: To test the accuracy of the integrated biopsy system in phantoms and animals. The complete biopsy system will also be tested in a small number of human patients. Our FACBC patient studies are supported by the NIH-sponsored imaging center program (P50CA128301) and by the Phase II Clinical Trial (NCT00562315). The mechanically assisted device has received the FDA 510K approval. The proposed study will promote the academic-industrial collaboration (Emory University, Robarts Research Institute of the University of Western Ontario, and Eigen Inc., Grass Valley, CA). If completely developed, the multimodality molecular image-guided system will be able to be used not only for biopsy but also for brachytherapy, radiofrequency thermal ablation, cryotherapy, and photodynamic therapy.

描述（由申请人提供）：前列腺癌在美国影响六分之一的男性。 45岁以上的每个人都有前列腺癌的风险。系统的转直肠超声（TRUS）指导活检是预先诊断前列腺癌的标准方法。每年进行超过120万个前列腺活检，每年的医疗费用超过20亿美元。但是，该技术具有明显的采样误差，其特征是低灵敏度（39-52％）。这种“盲”活检方法可能会错过30％的前列腺癌。由于阴性活检并不能排除错过癌症的可能性，因此医生和患者在做出治疗决策方面都面临着挑战。由于年轻男性的潜在早期和可治愈的前列腺癌的数量增加，因此必须解决此问题，以提高癌症检测率。在我们的NIH/NCI支持的Emory分子和翻译成像中心，具有新的分子成像示踪剂FACBC的正电子发射断层扫描（PET）在人类患者的前列腺癌检测结果上表现出非常有希望的结果。我们假设FACBC PET分子图像可以纳入超声引导的活检中，以改善癌症检测。拟议的研究是开发一个分子图像指导的3D超声引导系统，以靶向前列腺活检。特定目标1：修改实时辅助的3D超声引导设备。与常规的2D图像指南相比，前列腺的3D图像将用于指导活检。特定目的2：为前列腺的3D超声图像开发基于快速变形和统计外观模型的分割方法。统计形状模型将从我们的数据库开发，并将用于指导前列腺的自动分割。特定目标3：将FACBC分子图像与3D超声相结合，以进行靶向活检。为了解决基于信息的图像注册的主要局限性，将开发基于新的可变形图像登记方法的新图像注册方法。特定目的4：测试幻影和动物中综合活检系统的准确性。完整的活检系统也将在少数人类患者中进行测试。我们的FACBC患者研究得到了NIH赞助的成像中心计划（P50CA128301）和II期临床试验（NCT00562315）的支持。机械辅助设备已获得FDA 510K批准。拟议的研究将促进学术工业合作（Emory University，Western Ontario大学Robarts研究所和加利福尼亚州格拉斯谷的Eigen Inc.）。如果完全开发，多模式的分子图像引导系统将不仅可以用于活检，还可以用于近距离放射治疗，射频热消融，冷冻疗法和光动力疗法。